tradmap

TMDX Financials Transmedics Group, Inc.

8 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →

Growth & profitability

  • Revenue has grown 88.2% per year over the past 5 years.
  • Operating margin has expanded, at 17.9% in the latest year.

Financial health

  • Total debt has grown slower than revenue (14.9% vs 88.2% per year).
  • Operating income covered interest expense 7.9× in the latest year.
Revenue & net income
-$44M $281M $605M $0 2018 2019 2020 2021 2022 2023 2024 2025
RevenueNet income
Margins (gross / operating / net)
-182% -56% 70% 0% 2018 2019 2020 2021 2022 2023 2024 2025
GrossOperatingNet
Return on equity & assets (ROE / ROA)
-65% -12% 40% 0% 2018 2019 2020 2021 2022 2023 2024 2025
ROEROA
Free cash flow (CFO − capex)
-$165M -$16M $134M $0 2018 2019 2020 2021 2022 2023 2024 2025
Free cash flow
Cash vs total debt
$0 $244M $489M 2018 2019 2020 2021 2022 2023 2024 2025
CashTotal debt
Cash flow: operating / investing / financing
-$194M $103M $400M $0 2018 2019 2020 2021 2022 2023 2024 2025
OperatingInvestingFinancing

Key annual figures

FYRevenueNet incomeGross MOp MROEROAFCFTotal debtCash
2025 $605M $190M 59.9% 17.9% 40.2% 17.8% $134M — $489M
2024 $442M $36M 59.4% 8.5% 15.5% 4.4% -$81M — $337M
2023 $242M -$25M 63.8% -11.9% -18.2% -3.5% -$165M — $395M
2022 $93M -$36M 69.8% -33.6% -19.3% -13.1% -$58M $59M $202M
2021 $30M -$44M 69.9% -130.3% -65.1% -32.8% -$32M $35M $26M
2020 $26M -$29M 64.9% -102.9% -27.7% -18.9% -$31M $35M $25M
2019 $24M -$34M 58.7% -125.4% -61.4% -31.9% -$32M $34M $21M
2018 $13M -$24M 44.1% -155.5% 12.4% -56.4% -$26M $34M $21M

Valuation over time

How the market has priced TMDX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.

Price / earnings (P/E)
0.0 71.4 142.7 Mar '23 Sep '23 Mar '24 Sep '24 Mar '25 Sep '25 Mar '26 Sep '26
P/E
Price / sales (P/S)
0.0 17.3 34.6 Mar '23 Sep '23 Mar '24 Sep '24 Mar '25 Sep '25 Mar '26 Sep '26
P/S

Frequently asked questions

Is TMDX growing its revenue and profit?

Over the past 5 years, Transmedics Group, Inc.'s revenue has grown 88.2% per year. These are computed facts, not advice.

How much debt does TMDX have?

As of FY2025, Transmedics Group, Inc. reported — of total debt against $489M of cash; operating income covered interest expense 7.9×.

What is TMDX's profit margin?

In FY2025, gross margin was 59.9%, operating margin 17.9%, and net margin 31.4%.

What is TMDX's P/E ratio?

Transmedics Group, Inc.'s P/E (TTM) is 15.21 as of the 2026-11-02 close — market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year, the same figure as on the TMDX stock page. The valuation chart above sets each month-end's price against the latest annual net income instead, so its latest point (about 12.1× as of Nov '26) can differ. These are computed facts, not advice.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.